Figure 1 | Scientific Reports

Figure 1

From: Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity

Figure 1

IL-2/IL-2 receptor blocking activity of BA9, BT942 and Daclizumab. (a) Characterization of anti-CD25 antibodies compared to isotype antibody in respect to blocking IL-2 signaling in a STAT5 phosphorylation assay using human PBMCs. PBMCs were co-cultured with 10 μg/mL antibody for 30 min, then 10 U/mL IL2 was added and cultured for 10 min. Isotype is a human IgG1 with kappa light chain (Crown Bio, C0001-2). Data were presented as mean ± SEM. (b) BA9 and BT942 do not alter activation and proliferation of CD8+ and CD4+ T cells in vitro IL-2 signaling by T cell activation assay. Antibodies were tested for 72 h at 10 µg/mL. Data were presented as mean ± SEM.

Back to article page